McKesson : XPOVIO (selinexor), FDA Approved for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL), Available at Biologics by McKesson

CARY, N.C., June 29, 2020-Biologics by McKesson, an independent specialty pharmacy specializing in oncology, rare diseases and other complex therapeutic areas, was selected by Karyopharm Therapeutics, Inc. as a specialty pharmacy provider for XPOVIO^® (selinexor) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

This indication was approved based on response rate under the U.S. Food and Drug Administration's (FDA's) Accelerated Approval Program, which was developed to allow for expedited approval of drugs that treat serious conditions and that fill an unmet medical need. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

XPOVIO was approved by the FDA for this second cancer indication on June 22, 2020 and is the company's first-in-class, Selective Inhibitor of Nuclear Export (SINE) compound. This treatment has been granted both Fast Track and Orphan Drug designations from the FDA.

XPOVIO was previously approved as the first and only nuclear export inhibitor that blocks Exportin 1 (XPO1) and is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PI), at least two immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody (mAb).^1,2

'We're excited to continue to be a part of the limited distribution network for XPOVIO,' said Allison Kinnarney, director of Clinical Programs for Biologics. 'RR DLBCL patients have limited treatment options available, and we are proud to work with Karyopharm to now offer these patients another option.'

Biologics specialty pharmacy is committed to and recognized for its quality level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply skilled care team works together to develop individualized care plans that address each patient's unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone [phone]), fax [phone]) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

¹XPOVIO (selinexor) [package insert].
²Data on file. Karyopharm Therapeutics.

PR Contact

Claire Crye
Public Relations
281-825-9927
[e-mail]

CARY, N.C., June 29, 2020-Biologics by McKesson, an independent specialty pharmacy specializing in oncology, rare diseases and other complex therapeutic areas, was selected by Karyopharm Therapeutics, Inc. as a specialty pharmacy provider for XPOVIO^® (selinexor) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

This indication was approved based on response rate under the U.S. Food and Drug Administration's (FDA's) Accelerated Approval Program, which was developed to allow for expedited approval of drugs that treat serious conditions and that fill an unmet medical need. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

XPOVIO was approved by the FDA for this second cancer indication on June 22, 2020 and is the company's first-in-class, Selective Inhibitor of Nuclear Export (SINE) compound. This treatment has been granted both Fast Track and Orphan Drug designations from the FDA.

XPOVIO was previously approved as the first and only nuclear export inhibitor that blocks Exportin 1 (XPO1) and is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PI), at least two immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody (mAb).^1,2

'We're excited to continue to be a part of the limited distribution network for XPOVIO,' said Allison Kinnarney, director of Clinical Programs for Biologics. 'RR DLBCL patients have limited treatment options available, and we are proud to work with Karyopharm to now offer these patients another option.'

Biologics specialty pharmacy is committed to and recognized for its quality level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply skilled care team works together to develop individualized care plans that address each patient's unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone [phone]), fax [phone]) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

¹XPOVIO (selinexor) [package insert].
²Data on file. Karyopharm Therapeutics.

PR Contact

Claire Crye
Public Relations
281-825-9927
[e-mail]